- In April 2022, Antios Therapeutics, Inc., an international biopharmaceutical company, developed innovative therapies aimed at managing chronic Hepatitis D virus infections. Recently, the U.S. Patent and Trademark Office granted a patent for their application involving phosphoramidates for treating Hepatitis D virus. This patent includes the new Active Site Polymerase Inhibitor Nucleotide (ATI-2173) among various treatments and processes developed by Antios
- In June 2022, a virtual event called the “World Hepatitis Summit (WHS)” was held, bringing together global stakeholders committed to eliminating viral hepatitis. The summit served as a critical platform for exchanging insights, progress updates, and best practices across affected regions
